Phenyltoloxamine

證據等級: L5

預測適應症: 10 個

Phenyltoloxamine: From Antihistamine Adjuvant Use to Allergic Urticaria

One-Sentence Summary

Phenyltoloxamine is a first-generation H1 antihistamine typically used as a component of combination cold/allergy products; a distinct original indication for the single ingredient is not established in the available data. The TxGNN model predicts it may be effective for Allergic Urticaria, but this ranking is currently supported only by drug-class mechanistic reasoning — no clinical trials or published literature specific to this drug-indication pair have been identified.

Quick Overview

Item	Content
Original Indication	Not established in available data — phenyltoloxamine is a first-generation H1 antihistamine typically used within combination products, not marketed as a standalone entity
Predicted New Indication	Allergic Urticaria
TxGNN Prediction Score	96.24%
Evidence Level	L4
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (flagged as a High-severity data gap). Based on known pharmacology, phenyltoloxamine is classified as a first-generation H1 antihistamine, most often encountered as one component of multi-ingredient cold/allergy/analgesic combination products (e.g., Sinutab-type formulations) rather than as a standalone therapeutic agent with its own approved indication.

Allergic urticaria is a classic histamine-mediated condition — mast cell degranulation releases histamine, which acts on H1 receptors to increase vascular permeability and trigger the wheal-and-flare/pruritus response. H1 antihistamine blockade is the established first-line pharmacological approach for this condition across the drug class, which is the basis for this prediction.

However, this is a class-effect (mechanistic) argument, not evidence specific to phenyltoloxamine itself. No clinical trial or literature has evaluated phenyltoloxamine, alone or in combination, for allergic urticaria specifically. The one trial identified for this drug in the broader evidence pack (NCT00378144, for a related indication — pharyngitis/nasal congestion) evaluated a multi-ingredient product (Sinutab), making it impossible to isolate phenyltoloxamine’s independent contribution even there.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: Key warnings, contraindications, and drug-drug interaction data for phenyltoloxamine are currently unavailable (flagged as a Blocking-severity data gap), which by itself precludes a preliminary safety assessment.

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking-severity data gap exists — professional information (warnings/contraindications) is unavailable, which prevents any preliminary safety evaluation.
The top-ranked prediction (allergic urticaria) is supported only by drug-class mechanistic plausibility (Evidence Level L4), with zero drug-specific clinical trials or literature.
The product is not currently marketed in South Africa (0 registrations), so there is no existing local safety or usage experience to draw on.

To proceed, the following is needed:

Product-specific Professional Information (warnings, contraindications, dosing) from the regulatory source
Detailed mechanism of action (MOA) data from DrugBank or equivalent
Literature or trial evidence evaluating phenyltoloxamine specifically (not only as a component of multi-ingredient products) for allergic urticaria
A determination of market entry/registration pathway if further development is pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.